Junyu Long

List of Publications by Year
in descending order

55	1,686	430754	345118
papers	citations	18	36
		h-index	g-index

57	57	57	1882
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer. Cancer Immunology, Immunotherapy, 2022, , 1.	2.0	8
2	A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Medicine, 2022, 14, 20.	3.6	26
3	Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma. Frontiers in Oncology, 2022, 12, 785535.	1.3	6
4	eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia. Frontiers in Molecular Biosciences, 2022, 9, 877117.	1.6	1
5	Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers.. Journal of Clinical Oncology, 2022, 40, e16155-e16155.	0.8	2
6	Genomic characterization and translational immunotherapy of microsatellite instability-high (MSI-H) in cholangiocarcinoma.. Journal of Clinical Oncology, 2022, 40, 4101-4101.	0.8	0
7	Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis. Briefings in Bioinformatics, 2021, 22, .	3.2	46
8	The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study. Frontiers in Oncology, 2021, 11, 646979.	1.3	23
9	Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 765-765.	0.7	3
10	Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 596573.	1.3	7
11	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. , 2021, 9, e001942.		22
12	Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 74, 1493-1494.	1.8	3
13	Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 673248.	2.2	4
14	Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer. Cancers, 2021, 13, 3343.	1.7	14
15	Association of chronic liver disease with the prognosis of COVID-19 patients. Journal of Hepatology, 2021, , .	1.8	1
16	Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. International Immunopharmacology, 2021, 96, 107610.	1.7	9
17	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. BMC Medicine, 2021, 19, 154.	2.3	32
18	Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. Hepatobiliary Surgery and Nutrition, 2021, 10, 434-442.	0.7	28

#	Article	IF	Citations
19	Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. Nature Communications, 2021, 12, 4753.	5.8	12
20	Racial/Ethnic Differences in the 21-Gene Recurrence Score Assay Among Women With Breast Cancer. JAMA Oncology, 2021, 7, 1248.	3.4	0
21	Genomic instability in lower-grade glioma: Prediction of prognosis based on lncRNA and immune infiltration. Molecular Therapy - Oncolytics, 2021, 22, 431-443.	2.0	6
22	Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. Journal of Cancer, 2021, 12, 1555-1562.	1.2	7
23	Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics, 2021, 11, 4585-4598.	4.6	39
24	Identification of TMB, CD8 T‑cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‑PD‑1/PD‑L1 therapy. Clinical and Translational Medicine, 2021, 11, e598.	1.7	0
25	Differential genes and scoring criteria among immunogenomic clusters of lower-grade gliomas. International Immunopharmacology, 2021, 101, 108376.	1.7	4
26	Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. , 2021, 9, e003334.		101
27	Identification and Validation of Constructing the Prognostic Model With Four DNA Methylation-Driven Genes in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 709669.	1.8	3
28	Application of the Lung Immune Prognostic Index From Research to Clinical Practice. JAMA Oncology, 2020, 6, 299.	3.4	0
29	Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma. International Immunopharmacology, 2020, 89, 107135.	1.7	17
30	Expression of p42.3 in non-small cell lung cancer. Annals of Translational Medicine, 2020, 8, 819-819.	0.7	7
31	Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 414-424.	0.7	93
32	Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes. International Journal of Biological Sciences, 2020, 16, 1153-1165.	2.6	45
33	Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093248.	1.4	10
34	Dyslipidemia Might Be Associated with an Increased Risk of Osteoarthritis. BioMed Research International, 2020, 2020, 1-9.	0.9	20
35	CeRNA regulatory network-based analysis to study the roles of noncoding RNAs in the pathogenesis of intrahepatic cholangiocellular carcinoma. Aging, 2020, 12, 1047-1086.	1.4	27
36	T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. American Journal of Cancer Research, 2020, 10, 4585-4606.	1.4	8

#	Article	IF	Citations
37	CK20 and lymph node involvement predict adverse outcome of malignant intraductal papillary neoplasm of the bile duct. Histology and Histopathology, 2020, 35, 449-456.	0.5	2
38	Construction and Investigation of a lncRNA-Associated ceRNA Regulatory Network in Cholangiocarcinoma. Frontiers in Oncology, 2019, 9, 649.	1.3	32
39	DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Theranostics, 2019, 9, 7251-7267.	4.6	99
40	Transcriptomic analysis and identification of prognostic biomarkers in cholangiocarcinoma. Oncology Reports, 2019, 42, 1833-1842.	1.2	16
41	Alterations in DNA Damage Repair Genes in Primary Liver Cancer. Clinical Cancer Research, 2019, 25, 4701-4711.	3.2	74
42	Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma. Cancer Cell International, 2019, 19, 90.	1.8	90
43	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. Journal of Hematology and Oncology, 2019, 12, 42.	6.9	58
44	Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine, 2019, 42, 363-374.	2.7	257
45	Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression. Journal of Cellular Physiology, 2019, 234, 18837-18848.	2.0	103
46	The diagnostic and prognostic role of RhoA in hepatocellular carcinoma. Aging, 2019, 11, 5158-5172.	1.4	16
47	Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. Annals of Translational Medicine, 2019, 7, 467-467.	0.7	24
48	Metabolic syndrome and the risk of cholangiocarcinoma: a hospital-based case&ndash;control study in China. Cancer Management and Research, 2018, Volume 10, 3849-3855.	0.9	13
49	A fourâ€geneâ€based prognostic model predicts overall survival in patients with hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2018, 22, 5928-5938.	1.6	128
50	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. BMC Cancer, 2018, 18, 766.	1.1	42
51	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology and Oncology, 2017, 10, 146.	6.9	77
52	Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing. Oncotarget, 2017, 8, 60358-60367.	0.8	8
53	Systematic review and meta-analysis: cholecystectomy and the risk of cholangiocarcinoma. Oncotarget, 2017, 8, 59648-59657.	0.8	13
54	Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Genes. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
55	Lenvatinib Plus PD-1 Blockade in Refractory or Unresectable Biliary Tract Carcinoma: Insights from Real-World Evidences. SSRN Electronic Journal, 0, , .	0.4	0